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INTRODUCTION
The Polycomb group (PcG) gene Bmi1 determines the proliferative potential of normal and leukemic stem cell 1 and is required for the self-renewal of hematopoietic and neural stem cells. [1] [2] [3] Self-renewal ability is one of the essential defining properties of a pluripotent stem cell-like phenotype distinguishing stem cells from many other cell types. 4 Bmi1 oncogene is expressed in all primary myeloid leukemia and leukemic cell lines analyzed so far 1, 5 and overexpression of Bmi1 causes neoplastic transformation of lymphocytes. 6, 7 Recent experimental observations documented an increased Bmi1 expression in human nonsmall-cell lung cancer, 8 human breast carcinomas, 9,10 human medulloblastomas, 11 prostate carcinomas, 12 and colon cancer, 13 suggesting that an oncogenic role of the Bmi1 activation may be extended beyond the leukemia and, perhaps, may affect progression of the epithelial malignancies and other solid tumors as well.
Increased expression of another PcG protein Ezh2 was documented in multiple types of human cancer, including hematological malignancies; [14] [15] [16] [17] [18] prostate carcinomas; [19] [20] [21] [22] breast carcinomas; 21, [23] [24] [25] [26] bladder carcinomas; 27,28 cutaneous melanomas; 21 bronchial squamous cell carcinomas; 29 multiple myelomas. 30 Initial experimental evidence supports the hypothesis that Ezh2 may function as a bona fide human oncogene. 23, 31 Consistent with this idea, several studies demonstrated Ezh2 amplification in human cancer cell lines and clinical tumor samples. 22, 31, 32 Recent experimental evidence support the hypothesis that increased expression of the BMI1 oncogene is one of the key regulatory factors determining a cellular phenotype captured by the expression of a death-from-cancer signature in a broad spectrum of therapy-resistant clinically lethal malignancies. 12, 33, 34 A mouse/human comparative translational genomics approach was utilized to identify the 11-gene signature distinguishing stem cells with normal self-renewal function versus stem cells with diminished self-renewal ability due to the loss of the BMI1 gene and similarly expressed in metastatic prostate tumors. 12, 33, 34 Distant metastatic lesions consistently display a stem cell-like expression profile of the 11-gene signature as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. Cancer patients with a stem cell-like expression profile of the 11-gene signature in primary prostate tumors had a significantly higher probability of disease recurrence after radical prostatectomy and diminished likelihood of the relapse-free survival after therapy. 12 Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with multiple types of cancer. 12, 33, 34 These data suggest that a conserved BMI1 oncogene-associated pathway, such as the PcG chromatin silencing pathway, [35] [36] [37] [38] [39] [40] might be similarly activated in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a therapy resistance phenotype. Here we tested the validity of this concept with respect to the metastatic prostate cancer and demonstrated that PcG pathway appears activated in a majority of clinical samples of prostate adenocarcinoma and overexpression of both BMI1 and Ezh2 oncoproteins is essential for malignant behavior in vivo of human prostate carcinoma metastasis precursor cells.
MATERIALS AND METHODS
Clinical samples. Two clinical outcome sets comprising 21 (outcome set 1) and 79 (outcome set 2) samples were utilized for analysis of the association of the therapy outcome with expression levels of the BMI1 and Ezh2 genes and other clinico-pathological parameters. Original gene expression profiles of the 21 clinical samples analyzed in this study were reported elsewhere. 41 Primary gene expression data files of clinical samples as well as associated clinical information can be found at www-genome.wi.mit.edu/cancer/.
Prostate tumor tissues comprising second clinical outcome set were obtained from 79 prostate cancer patients undergoing therapeutic or diagnostic procedures performed as part of routine clinical management at the Memorial Sloan-Kettering Cancer Center (MSKCC). Clinical and pathological features of 79 prostate cancer cases comprising validation outcome set are presented elsewhere. 12, 42 Median follow-up after therapy in this cohort of patients was 70 months. Samples were snap-frozen in liquid nitrogen and stored at -80˚C. Each sample was examined histologically using H&E-stained cryostat sections. Care was taken to remove non-neoplastic tissues from tumor samples. Cells of interest were manually dissected from the frozen block, trimming away other tissues. All of the microarray studies analyzed in this paper were previously published and were conducted under MSKCC Institutional Review Board-approved protocols. Overall, 146 human prostate tissue samples were analyzed in this study, including forty-six samples in a tissue microarray (TMA) format. TMA samples analyzed in this study were exempt according to the NIH guidelines.
Cell culture. Cell lines used in this study were previously described. 32, [42] [43] [44] [45] The LNCap-and PC-3-derived cell lines were developed by consecutive serial orthotopic implantation, either from metastases to the lymph node (for the LN series), or reimplanted from the prostate (Pro series). This procedure generated cell variants with differing tumorigenicity, frequency and latency of regional lymph node metastasis. 32, [42] [43] [44] [45] Except where noted, cell lines were grown in RPMI1640 supplemented with 10% FBS and gentamycin (Gibco BRL) to 70-80% confluence and subjected to serum starvation as described, 32, [42] [43] [44] [45] or maintained in fresh complete media, supplemented with 10% FBS.
Anoikis assay. Cells were harvested by 5-min digestion with 0.25% trypsin/0.02% EDTA (Irvine Scientific, Santa Ana, CA, USA), washed and resuspended in serum free medium. 12, 43, 44 Cells at concentration 1.7 x 10 5 cells/well in 1 ml of serum free medium were plated in 24-well ultra low attachment polystyrene plates (Corning Inc., Corning, NY, USA) and incubated at 37˚C and 5% CO 2 overnight. Viability of cell cultures subjected to anoikis assays were >95% in Trypan blue dye exclusion test.
Apoptosis assay. Apoptotic cells were identified and quantified using the Annexin V-FITC kit (BD Biosciences Pharmingen, www.bdbisciences.com) per manufacturer instructions. 12, 43, 44 The following controls were used to set up compensation and quadrants: (1) Unstained cells; (2) Cells stained with Annexin V-FITC (no PI); (3) Cells stained with PI (no Annexin V-FITC). Each measurements were carried out in quadruplicate and each experiments were repeated at least twice. Annexin V-FITC positive cells were scored as early apoptotic cells; both Annexin V-FITC and PI positive cells were scored as late apoptotic cells; unstained Annexin V-FITC and PI negative cells were scored as viable or surviving cells. In selected experiments apoptotic cell death was documented using the TUNEL assay.
Flow cytometry. Cells were washed in cold PBS phosphatebuffered saline and stained according to manufacturer's instructions using the Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA). Flow analysis was performed by a FACS Calibur instrument (BD Biosciences, San Jose, CA, USA). Cell Quest Software was used for data acquisition and analysis. All measurements were performed under the same instrument setting, analyzing 10 3 -10 4 cells per sample 12, 43, 44 .
Immunofluorescence microscopy. Cells fixed with 3.7% paraformaldehyde in phosphate-buffered saline (PFA/PBS) for 15 min were permeabilized with 0.5% Triton-X100 (Sigma, St.Louis, Mo, USA)/PBS for 5 min. After washing in PBS, cells were incubated in PBS containing 100 mM glycine for 10 min. Primary antibodies were diluted in 0.5% BSA/0.05% gelatin cold water fish skin/ PBS, and cells were incubated in this buffer for 10 min before antibodies were applied for 16 hrs at room temperature. After washing in PBS buffer, cells were incubated with secondary antibodies at 1:500 dilution. Coverslips were mounted in Prolong (Molecular Probes, Inc.). Images were collected on an inverted microscope (OlympusIX70) equipped with a DeltaVision imaging system using a x 40 objective. Images were processed by softWoRx v.2.5 software (Applied Precision Inc., Issaquah, WA) and images were quantified with using ImageJ 1.29x software (http://rsb.info.nih.gov/ij).
Quantitative immunofluorescence analysis of the PcG protein expression was performed using human prostate cancer tissue microarrays (TMAs) representing 46 prostate tissue samples (thirty-nine cases of prostate cancer and seven cases of normal prostate). Analysis was carried-out on the prostate cancer TMAs from Chemicon (Temecula, CA; TMA #3202-4; four cancer cases and two cases of normal tissue; and TMA #1202-4; twenty five cases of cancer and five cases of normal tissue) and TMA of 10 cases of prostate cancer from the SKCC tumor bank (San Diego, CA). TMAs contain two 2.0 mm cores of each case and haematoxylin-and-eosin (H&E) sections which were used for visual selection of the pathological tissues, histological diagnosis, and grading by the pathologists of TMA providers.
Four-or five-micrometer paraffin-embedded sections were baked at 56˚C for 1 hour, allowed to cool for about 5 minutes, dewaxed in xylene, and rehydrated in a series of graded alcohols. Antigen retrieval was achieved by boiling slides in 10mM sodium citrate buffer, 0.05% Tween 20, pH 6.0 in a water bath for 30 minutes. The sections were washed with PBS, incubated in 100 mM glycine/PBS for 10 minutes, blocked in 0.5% BSA/0.05% gelatine cold water fish skin/PBS and incubated with primary antibody overnight.
Primary antibodies were EZH2 rabbit polyclonal antibody (1:50), BMI1 mouse monoclonal IgG1 antibody (1:50), ubiH2A mouse IgM (1:100), 3metK27 rabbit polyclonal antibody (1:100) (Upstate, Lake Placid, NY). Suz12 rabbit (1:50), AMACR rabbit (1:50) antibodies and Dicer mouse IgG1 (1:20) were purchased from Abcam (Cambridge, MA). BMI1 rabbit (1:50) and TRAP100 (1:50) goat antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Cyclin D1 rabbit polyclonal antibody (1:50) were from Biocare Medical (Concord, CA). EZH2 mouse monoclonal antibodies were kindly provided by Dr. A.P. Otte.
The primary antibodies were rinsed off with PBS and slides were incubated with secondary antibodies at 1:300 dilution for 1 hour at room temperature. Secondary antibodies (chicken antirabbit Alexa 594, goat antimouse Alexa 488, goat antimouse IgG1 Alexa 350, and donkey antigoat Alexa 488 conjugates) were from Molecular Probes (Eugene, OR). The slides were washed four times in PBS for five minutes each wash, rinsed in distilled water and the specimen were coversliped with Prolong Gold Antifade Reagent (Molecular Probes, Eugene, OR) containing DAPI. For negative controls, the primary antibodies were omitted. Three samples were excluded from analysis because one of the following reasons: core loss, unrepresentative sample, or sub-optimal DNA and antigen preservation.
Images were collected on an inverted fluorescent microscope (LEICA DMIRE 2 or Olympus IX70) using an x 40 objective. Images were processed by Leica FW4000 software and images were quantified with using ImageJ 1.29x software. Expression values were measured in at least 200 nuclei from two microscopic fields for each case.
The measurements were carried out in the nuclei of individual cells defined by DAPI staining both in experimental and clinical samples. For experimental samples, the comparison thresholds for each marker combination were defined at the 90-95% exclusion levels for dual positive cells in corresponding control samples (parental low metastatic cells). For clinical samples, the comparison thresholds for each marker combination were defined at the 99% or greater exclusion levels for dual positive cells in corresponding control samples (normal epithelial cells in TMA experiments). All individual immmunofluorescent assay experiments (defined as the experiments in which the corresponding comparisons were made) were carried out simultaneously using the same reagents and included all experimental samples and controls utilized for a quantitative analysis. Statistical significance of the measurements was ascertained and consistency of the findings was confirmed in multiple independent experiments, including several independent sources of the prostate cancer TMA samples.
Orthotopic xenografts. Orthotopic xenografts of human prostate PC-3 cells and prostate cancer metastasis precursor sublines used in this study were developed by surgical orthotopic implantation as previously described. 32, [42] [43] [44] [45] Briefly, 2 x 10 6 cultured PC-3 cells or sublines were injected subcutaneously into male athymic mice, and allowed to develop into firm palpable and visible tumors over the course of 2-4 weeks. Intact tissue was harvested from a single subcutaneous tumor and surgically implanted in the ventral lateral lobes of the prostate gland in a series of ten athymic mice per cell line subtype as described earlier. 32, [42] [43] [44] [45] During orthotopic cell inoculation experiments, a single-cell suspension of 1.5 x 10 6 cells was injected into mouse prostate gland in a series of ten athymic mice per therapy group.
siRNA experiments. The target siRNA SMART pools and chemically modified degradation-resistant variants of the siRNAs (stable siRNAs) for BMI1, Ezh2, and control luciferase siRNAs were purchased from Dharmacon Research, Inc. siRNAs were transfected into human prostate carcinoma cells according to the manufacturer's protocols. Cell cultures were continuously monitored for growth and viability and assayed for mRNA expression levels of BMI1, Ezh2, and selected set of genes using RT-PCR and Q-RT-PCR methods. Eight individual siRNA sequences comprising the SMART pools (four sequences for each gene, BMI1 and Ezh2) were tested and a single most effective siRNA sequence was selected for synthesis in the chemically modified stable siRNA form for each gene. We designed the siRNA treatment protocol [two consecutive treatments of cells in adherent cultures with 100 nM (final concentration) of Dharmacon degradation-resistant siRNAs at day 1 and 4 after plating] causing only moderate reduction in the average BMI1 and Ezh2 protein expression levels (20-50% maximal effect) Polycomb Pathway and Cancer Metastasis and having no or only marginal effect on cell proliferation in the adherent cultures (at most ~25% reduction in cell proliferation).
Quantitative RT-PCR analysis. The real time PCR methods measures the accumulation of PCR products by a fluorescence detector system and allows for quantification of the amount of amplified PCR products in the log phase of the reaction. Total RNA was extracted using RNeasy mini-kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. A measure of 1 μg (tumor samples), or 2 μg and 4 μg (independent preparations of reference cDNA and DNA samples from cell culture experiments) of total RNA was used then as a template for cDNA synthesis with SuperScript II (Invitrogen, Carlsbad, CA, USA). cDNA synthesis step was omitted in the DNA copy number analysis. 32 Q-PCR primer sequences were selected for each cDNA and DNA with the aid of Primer Express TM software (Applied Biosystems, Foster City, CA, USA). PCR amplification was performed with the gene-specific primers. 12, 32, [42] [43] [44] [45] Q-PCR reactions and measurements were performed with the SYBR-Green and ROX as a passive reference, using the ABI 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Conditions for the PCR were as follows: one cycle of 10 min at 95˚C; 40 cycles of 0.20 min at 94˚C; 0.20 min at 60˚C and 0.30 min at 72˚C. The results were normalized to the relative amount of expression of an endogenous control gene GAPDH.
Expression of messenger RNA (mRNA) and DNA copy number for target genes and an endogenous control gene (GAPDH) was measured by real-time PCR method on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems). For each gene at least two sets of primers were tested and the set-up with highest amplification efficiency was selected for the assay used in this study. Specificity of the assay for mRNA measurements was confirmed by the absence of the expected PCR products when genomic DNA was used as a template. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH: 5'-CCCTCAACGACCACTTTGTCA-3' and 5'-TTC-CTCTTGTGCTCTTGCTGG-3') was used as the endogenous RNA and cDNA quantity normalization control. 32 Expression and DNA copy number analysis analysis of all genes was assessed at least in two independent experiments using reference cDNAs to control for variations among different Q-RT-PCR experiments. Prior to statistical analysis, the normalized gene expression values were log-transformed (on a base 10 scale) similarly to the transformation of the array-based gene expression data.
Survival analysis. The Kaplan-Meier survival analysis was carried out using the GraphPad Prism version 4.00 software (GraphPad Software, San Diego, CA; www.graphpad.com). The end point for survival analysis in prostate cancer was the biochemical recurrence defined by the serum PSA increase after therapy. Disease-free interval (DFI) was defined as the time period between the date of radical prostatectomy (RP) and the date of PSA relapse (recurrence group) or date of last follow-up (non-recurrence group). Statistical significance of the difference between the survival curves for different groups of patients was assessed using Chi square and Log-rank tests. To evaluate the incremental statistical power of the individual covariates as predictors of therapy outcome and unfavorable prognosis, we performed both univariate and multivariate Cox proportional hazard survival analyses. Clinico-pathological covariates included in this analysis were: preoperative PSA, Gleason score, surgical margins, extra-capsular invasion, seminal vesicle invasion, and age.
RESULTS
Activation of PcG protein chromatin silencing pathway in human prostate carcinoma metastasis precursor cells. PcG pathway activation hypothesis implies that individual cells with activated chromatin silencing pathway would exhibit a concomitant nuclear expression of both BMI1 and Ezh2 proteins. Furthermore, cells with activated PcG pathway would manifest the increased expression levels of protein substrates targeted by the activation of corresponding enzymes to catalyze the H2A-K119 ubiquitination (BMI1-containing PRC1 complex) and H3-K27 methylation (Ezh2-containing PRC2 complex). [35] [36] [37] [38] [39] [40] Observations that increased BMI1 expression is associated with metastatic prostate cancer 12 suggest that PcG pathway might be activated in metastatic human prostate carcinoma cells. Consistent with this idea, previous independent studies documented an association of the increased Ezh2 expression with metastatic disease in prostate cancer patients. 19 We therefore applied immunofluorescence analysis to measure the expression of protein markers of the PcG pathway activation in prostate cancer metastasis precursor cells isolated from blood of nude mice bearing orthotopic human prostate carcinoma xenografts. 43, 44 Immunofluorescence analysis reveals that expression of all four individual protein markers of PcG pathway activation is elevated in blood-borne human prostate carcinoma metastasis precursor cells compared to the parental cells comprising a bulk of primary tumors ( Figs. 1 and 2) . To document the PcG pathway activation in individual cells, we carried out the quantitative immunofluorescence colocalization analysis allowing for a simultaneous detection and quantification of several markers in a single cell. The quantitative immunofluorescence colocalization analysis demonstrates a marked enrichment of the population of blood-borne human prostate carcinoma metastasis precursor cells with the dual positive high BMI1/Ezh2-expressing cells (Fig. 1A) . These results were confirmed using two different mouse/rabbit primary antibody combinations for BMI1 and Ezh2 protein detection as well as different secondary fluorescent antibodies. Similar enrichment for the PcG pathway activated cells in a pool of circulating metastasis precursor cells is evident for other two-marker combination panels as well (Fig. 2) . In contrast to the protein markers of the PcG pathway activation, a significantly smaller fraction of cells expressing concomitantly high levels of the cytoplasmic AMACR/nuclear p63 proteins was detected in human prostate carcinoma metastasis precursor cells compared to the parental cell population (data not shown). Therefore, the results of a quantitative immunofluorescence colocalization analysis seems to indicate that measurements of several two-marker combinations demonstrate a significant enrichment of the population of prostate carcinoma metastasis precursor cells with the cells expressing high levels of the PcG pathway activation markers (Figs. 1 and 2 ). We and other previously documented that increased BMI1 and Ezh2 mRNA expression is associated with metastatic prostate cancer. 12, [19] [20] [21] [22] Taken together these data support the hypothesis that PcG chromatin silencing pathway is activated in blood-borne human prostate carcinoma metastasis precursor cells and might contribute to the ability of metastatic cancer cells to survive and grow at distant sites.
Amplification of the BMI1 and Ezh2 genes in multiple experimental models of human prostate cancer. Increased expression of oncogenes is often associated with gene amplification. In agreement with proposed oncogenic role of the BMI1 and Ezh2 overexpression in human prostate carcinoma cells, we documented a significant amplification of both BMI1 and Ezh2 genes in human prostate carcinoma cell lines representing multiple experimental models of metastatic prostate cancer (Fig. 1E) . Notably, the level of gene amplification as determined by the measurement of DNA copy number for both BMI1 and Ezh2 genes is higher in metastatic cancer Polycomb Pathway and Cancer Metastasis Figure 2 . Activation of the PcG chromatin silencing pathway in metastatic human prostate carcinoma cells. A quantitative immunofluorescence colocalization analysis was utilized to measure the expression of the BMI1, Ezh2, H3metK27 and UbiH2A markers in human prostate carcinoma cells and calculate the numbers of dual-positive cells expressing various two-marker combinations. Note that high expression of the BMI1 and Ezh2 oncoproteins in PC-3-32 human prostate carcinoma metastasis precursor cells compared to parental PC-3 cells is associated with increased levels of histone H3 lysine 27 methylation (H3metK27), histone H2A lysine 119 ubiquitination (UbiH2A) and marked enrichment for dual-positive cell populations expressing high levels of BMI1/UbiH2A, Ezh2/H3metK27 and H3metK27/UbiH2A two-marker combinations.
cell variants compared to the nonmetastatic or less malignant counterparts, suggesting that gene amplification may play a casual role in elevation of the BMI1 and Ezh2 oncoprotein expression levels and high BMI1/Ezh2-expressing cells may acquire a competitive survival advantage during tumor progression. These results are in agreement with the previous studies demonstrating amplification of the Ezh2 gene in human cancer cell lines and clinical tumor samples. 22, 31, 32 PcG pathway activation renders circulating human prostate carcinoma metastasis precursor cells resistant to anoikis. To ascertain the biological role of the PcG pathway activation in prostate cancer metastasis, human prostate carcinoma metastasis precursor cells were isolated from the blood of nude mice bearing orthotopic human prostate carcinoma xenografts, 43, 44 transfected with BMI1, Ezh2, or control siRNAs, and continuously monitored for mRNA and protein expression levels of BMI1, Ezh2, and a set of additional genes and protein markers using inmmunofluorescence analysis, RT-PCR, and Q-RT-PCR methods. Q-RT-PCR and RT-PCR analyses showed that siRNA-mediated BMI1-silencing caused ~90% inhibition of the endogenous BMI1 mRNA expression. The effect of siRNA-mediated BMI1 silencing was validated at the protein expression level using immunofluorescence analysis (Fig. 3) . The BMI1 silencing was specific since the expression levels of nine un-related transcripts were not altered (Fig. 3) . Consistent with the hypothesis that expression of genes comprising the 11-gene death-from-cancer signature is associated with the expression of the BMI1 gene product, mRNA abundance levels of 8 of 11 interrogated BMI1-pathway target genes were altered in the human prostate carcinoma cells with siRNA-silenced BMI1 gene. 12 For biological analysis we adopted the silencing protocol resulting in 80-100% reduction of the level of dual-positive BMI1/ Ezh2 high-expressing metastasis precursor cells, thus yielding the cell population more closely resembling nontreated parental cells and markedly distinct from metastasis precursor cells treated with control siRNA (Figs. 3 and 4) .
Reduction of the BMI1 mRNA and protein expression in human prostate carcinoma metastasis precursor cells did not alter significantly the viability of adherent cultures grown at the optimal growth condition and in serum starvation experiments. siRNA treatment had only modest inhibitory effect on proliferation causing ~25% reduction in the number of cells. However, the ability of human prostate carcinoma cells to survive in nonadherent state was severely Anoikis-resistant PC-3-32 prostate carcinoma cells 43, 44 were treated with BMI1-or Ezh2-targeting siRNAs and continuously monitored for expression levels of the various mRNAs, BMI and Ezh2 oncoproteins, as well as cell growth and viability under various culture conditions. PC-3-32 cells with reduced expression of either BMI1 or Ezh2 oncoproteins acquired sensitivity to anoikis as demonstrated by the loss of viability and increased apoptosis compared to the control LUC siRNA-treated cultures growing in detached conditions. Note that targeted siRNA-mediated downregulation of expression of either BMI1 (A) or Ezh2 (B) oncoproteins causes similar loss of anoikis resistance in human prostate carcinoma metastasis precursor cells.
Polycomb Pathway and Cancer Metastasis affected after siRNA-mediated reduction of the BMI1 expression (Fig. 3) . FACS analysis revealed ~3-fold increase of apoptosis in the BMI1 siRNA-treated human prostate carcinoma cells cultured in nonadherent conditions (Fig. 3) . These data suggest that human prostate carcinoma cells expressing high level of the BMI1 protein are more resistance to apoptosis induced in cells of epithelial origin in response to attachment deprivation (anoikis). It is likely that these anoikis-resistant cancer cells would survive better in blood or lymph during metastatic dissemination thus forming a pool of circulatory stress-surviving metastasis precursor cells. 12, 43, 44 Similar results were obtained when Ezh2 silencing experiments were performed (Fig. 3) , suggesting that targeting of either PRC1 or PRC2 complexes is sufficient for interference with the PcG pathway activity and inhibition of anoikis-resistance mechanisms in metastatic prostate carcinoma cells. Thus, downregulation of either BMI1 or Ezh2 expression in metastatic human prostate carcinoma cells is associated with diminished resistance to anoikis and increased apoptosis in non-adherent cultures (Fig. 3) , suggesting that dual-positive high BMI1/ Ezh2-expressing carcinoma cells may acquire a selective survival advantage during the passage through lymph and/or blood compartments. levels of targeted proteins for extended period of time (~30-50% reduction at the 11 days post-treatment time point) compared to the cells treated with the control LUC siRNA (Fig. 4) . Importantly, the siRNA-treated human prostate carcinoma cell populations were essentially depleted for dual positive high BMI1/Ezh2-expressing carcinoma cells (Fig. 4) thus setting up the stage for critical in vivo analysis using a fluorescent orthotopic model of human prostate cancer metastasis in nude mice. 43, 44 Remarkably, highly malignant human prostate carcinoma cell populations depleted for dual positive high BMI1/Ezh2-expressing cells demonstrated markedly diminished tumorigenic and metastatic potential in vivo (Fig. 5) . Within three weeks after inoculation of the 1.5 x 10 6 of tumor cells, 100% of control animals developed rapidly growing highly invasive and metastatic carcinomas in the mouse prostate and all animal died within 50 days of the experiment (Fig. 5) . In contrast, only 20% of animals in both BMI1-and Ezh2-targeting therapy groups developed seemingly less malignant tumors causing death of hosts 78-87 days after tumor cell inoculation (Fig. 5) . Significantly, 150 days after tumor cell inoculation 83% and 67% of animals remain alive and disease-free in the therapy groups targeting the BMI1 and Ezh2 proteins, respectively ( Fig. 5 ; p = 0.0007, Log rank test).
Increased levels of dual positive high BMI/Ezh2-expressing cells indicate activation of the PcG pathway in a majority of human prostate adenocarcinomas. To validate the significance of our findings for human disease, we applied the quantitative immunofluorescence colocalization analysis for measurements of the expression of BMI1 and Ezh2 proteins and detection of dual positive high BMI/ Ezh2-expressing carcinoma cells in clinical samples obtained from patients diagnosed with prostate adenocarcinomas. The results of this analysis demonstrate that a majority (79-91% in different cohorts of patients) of human prostate tumors contains dual positive high BMI1/Ezh2-expressing carcinoma cells exceeding the threshold expression level in prostate samples from normal individuals (Fig. 6) . Interestingly, a panel of adenocarcinoma samples appears quite heterogeneous with respect to the relative levels of dual positive high BMI1/Ezh2-expressing cells (Fig. 6) . While in 50-74% of prostate tumors the level of high BMI1-, high Ezh2-or dual positive high BMI1/Ezh2-expressing cells was only slightly elevated (<15% of positive cells), a significant fraction (17-29%) of prostate adenocarcinomas demonstrates a marked enrichment for dual positive high Increased BMI1 and Ezh2 expression is associated with high likelihood of therapy failure in prostate cancer patients after radical prostatectomy. Microarray analysis demonstrates that cancer patients with high levels of BMI1 and Ezh2 mRNA expression in prostate tumors have a significantly worst relapse-free survival after radical prostatectomy (RP) compared with the patients having low levels of BMI1 and Ezh2 expression (Fig. 7) , suggesting that more profound alterations of the PcG protein chromatin silencing pathway in carcinoma cells are associated with therapy resistant clinically lethal prostate cancer phenotype. We carried out the multivariate Cox proportional hazards survival analysis to ascertain the prognostic power of measurements of BMI1 and Ezh2 expression in combination with known clinical and pathological markers of prostate cancer therapy outcome such as Gleason score, surgical margins, extracapsular invasion, seminal vesicle invasion, serum PSA levels, and age. Of note, BMI1 expression level remains a statistically significant prognostic marker in the multivariate analysis ( Table 1) . Application of the 8-covariate prostate cancer recurrence model combining the incremental statistical power of individual prognostic markers appears highly informative in stratification of prostate cancer patients into sub-groups with differing likelihood of therapy failure and disease relapse after radical prostatectomy (Fig. 7) . One of the distinctive features of this model is that it identifies a sub-group of prostate cancer patients comprising bottom 20% of recurrence predictor score and manifesting no clinical or biochemical evidence of disease relapse (Fig. 7) . In contrast, 80% of patients in a subgroup comprising top 20% of recurrence predictor score failed therapy within five year period after radical prostatectomy.
DISCUSSION
Increasing experimental evidence suggest that an oncogenic role of the BMI1 activation may be extended beyond the leukemia and, perhaps, play a key role in progression of the epithelial malignancies and other solid tumors as well (see Introduction). One of the compelling examples revealing an association of the activated BMI1 ocoprotein-driven pathway (s) with clinically lethal therapy-resistant malignant phenotype in patients diagnosed with multiple types of cancer is identification of a death-from-cancer gene expression signature. 12, 33, 34 An 11-gene signature distinguishes stem cells with normal self-renewal function versus stem cells with drastically diminished self-renewal ability due to the loss of the BMI-1 oncogene and similarly expressed in metastatic prostate tumors. 12 To date, the prognostic power of the 11-gene signature was validated in multiple independent therapy outcome sets of clinical samples obtained from more than 2,500 cancer patients diagnosed with 12 different types of cancer, including six epithelial (prostate; breast; lung; ovarian; gastric; and bladder cancers) and five nonepithelial (lymphoma; mesothelioma; medulloblastoma; glioma; and acute myeloid 43, 44 were treated with chemically modified degradation-resistant stable siRNAs targeting BMI1 or Ezh2 mRNAs or control LUC siRNA. Twenty-four hours after second treatment, 1.5 x 10 6 cells were injected into prostates of nude mice. Note that all control animals developed highly aggressive rapidly growing metastatic prostate cancer and died within 50 days of experiment (A). Only 20% of mice in the BMI1-and Ezh2-targeting therapy groups developed less malignant more slowly growing tumors. One hundred fifty days after tumor cell inoculation, 83% and 67% of animals remain alive and disease-free in the therapy groups targeting the BMI1 and Ezh2 oncoproteins, respectively (p = 0.0007; log-rank test) (B). Six animals per group were monitored for survival. 12, 33, 34 These data suggest the presence of a conserved BMI1 oncogene-driven pathway, which is similarly activated in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a therapy resistance phenotype. Taken together with the results of the present study these data support the hypothesis that activation of the PcG chromatin silencing pathway is one of the key regulatory factors determining a cellular phenotype captured by the expression of a death-from-cancer signature in therapy-resistant clinically lethal malignancies. Cancer cells with activated PcG pathway would be expected to exhibit a concomitantly high expression of both BMI1 and Ezh2 proteins. Furthermore, cells with activated PcG pathway would manifest the increased expression levels of protein substrates targeted by the activation of corresponding enzymes to catalyze the H2A-K119 ubiquitination (BMI1-containing PRC1 complex) and H3-K27 methylation (Ezh2-containing PRC2 complex). In this study we experimentally tested the relevance of this concept for metastatic prostate cancer. We applied a quantitative colocalization immunofluorescence analysis to measure the expression of four distinct protein markers of the PcG pathway activation and demonstrated a concomitantly increased expression of all four markers in a sub-population of human prostate carcinoma metastasis precursor cells isolated from the blood of nude mice bearing orthotopic metastatic human prostate carcinoma xenografts. Presence of dual positive high BMI1/Ezh2-expressing cells appears essential for maintenance of tumorigenic and metastatic potential of human prostate carcinoma cells in vivo, since targeted depletion of dual positive high BMI1/Ezh2-expressing cells from a population of highly metastatic human prostate carcinoma cells treated with stable siRNAs generates a cancer cell population with dramatically diminished malignant potential in vivo.
The BMI1 and Ezh2 proteins are members of the Polycomb group protein (PcG) chromatin silencing complexes conferring genome scale transcriptional repression via covalent modification of histones. 35 The BMI1 PcG protein is a component hPRC1L complex (human Polycomb repressive complex 1-like) which was recently identified as the E3 ubiquitin ligase complex that is specific for histone H2A and plays a key role in Polycomb silencing. 36 Ubiquitination/ deubiquitination cycle of histones H2A and H2B is important in regulating chromatin dynamics and transcription mediated, in part, via 'cross-talk' between histone ubiquitination and methylation. 37 Importantly, one of the upregulated genes in the 11-gene death-fromcancer signature profile (Rnf2) plays a central role in the PRC1 complex formation and function 36 thus complementing the BMI-1 function in the PRC1 complex. Rnf2 expression plays a crucial non-redundant role in development during a transient contact formation between PRC1 and PRC2 complexes via Rnf2 as described for Drosophila. 38, 39 The Ezh2 protein is a member of the Polycomb PRC2 and PRC3 complexes with a histone lysine methyltransferase (HKMT) activity that is associated with transcriptional repression due to chromatin silencing. The HKMT-Ezh2 activity targets lysine residues on histones H1 and H3 (H3-K27 or H1-K26). H3-K27 methylation conferred by an active HKMT-Ezh2-containing complex is one of the key molecular events essential for chromatin silencing in vivo. Taken together, these data imply that in vivo Polycomb chromatin silencing pathway in distinct cell types would require a coordinate activation of multiple distinct PRC complexes. For example, Ezh2 associates with different EED isoforms thereby determining the specificity of histone methyltransferase activity toward histone H3-K27 or histone H1-K26. 40 Collectively, these results suggest that coherent function of the PcG chromatin silencing pathway would require a concomitant coordinated activation of multiple protein components of PRC1, PRC2, and PRC3 complexes implying a coordinate regulation of expression of their essential components such as BMI1 and Ezh2 oncoproteins. It follows that dual positive high BMI1/Ezh2-expressing carcinoma cells with elevated expression of the H2AubiK119 and H3metK27 histones should be regarded as cells with activated PcG protein chromatin silencing pathway.
In human cells the BMI1-containing PcG complex forms a unique discrete nuclear structure that was termed the PcG bodies, 46 the size and number of which in nuclei significantly varied in different cell types. Of note, the nuclei of dual positive high BMI1/Ezh2-expressing cells almost uniformly contain six prominent discrete PcG bodies, perhaps, reflecting the high level of the BMI1 expression and indicating the active state of the PcG protein chromatin silencing pathway. It has been shown recently that in cancer cells expressing high level of the Ezh2 protein the new type of the PcG chromatin silencing complex is formed containing the Sirt1 protein. 47 These data suggest that in high Ezh2-expressing carcinoma cells a distinct set of genetic loci could be repressed due to activation of the Ezh2/Sirt1-containing PcG chromatin silencing complex.
One of the notable features of dual positive high BMI1/ Ezh2-expressing carcinoma cells is a prominent cytosolic expression of the Ezh2 oncoprotein (Fig. 1) . Recent evidence revealed the existence of the cytosolic Ezh2-containing methyltransferase complex Figure 6 . Tissue microarray analysis (TMA) of primary prostate tumors from patients diagnosed with prostate adenocarcinomas reveals increased levels of dual-positive BMI1/Ezh2 high-expressing cells. BMI1 and Ezh2 oncoprotein expression were measured in prostate TMA samples from cancer patients and healthy donors using a quantitative colocalization immufluorescence method and the number of dual positive high BMI1/Ezh2-expressing nuclei was calculated for each sample. Note that primary prostate tumors from patients diagnosed with prostate adenocarcinomas manifest a diverse spectrum of accumulation of dual positive BMI1/Ezh2 high-expressing cells and patients with higher levels of BMI1 or Ezh2 expression in prostate tumors manifest therapy-resistant malignant phenotype (Fig. 7) . A majority (79-92% in different cohorts of patients) of human prostate tumors contains dual positive high BMI1/Ezh2-expressing cells exceeding the threshold expression levels in prostate samples from normal individuals.
regulating actin polymerization and extra-nuclear signaling processes in various cell types. 48 It is possible that both nuclear and extra-nuclear functions of the Ezh2-containing methyltransferase complex may play an important role in determining the malignant behavior of metastatic human prostate carcinoma cells. Recent observations directly demonstrated that the PcG repressive complexes PRC1 and PRC2 cooccupied a large set of genes in human and murine genomes, many of which are transcriptional developmental regulators. 49, 50 These data suggest that repression of multiple developmental and differentiation pathways by Polycomb complexes may be required for maintaining stem cell pluripotency and add further support to the idea that repression of critical developmental regulators by PcG proteins may play a crucial role in tumor progression and metastasis.
The results of our experiments indicate that PcG pathway is frequently activated in human prostate tumors and is mechanistically linked to the highly malignant behavior of human prostate carcinoma cells in a xenograft model of prostate cancer metastasis. It remains to be elucidated whether similarly to the xenograft model of human prostate cancer metastasis in nude mice the PcG pathway activation is mechanistically associated with metastatic disease in prostate cancer patients as well. It will be of interest to study whether the level of enrichment of primary prostate tumors with dual positive high BMI1/Ezh2-expressing cancer cells would correlate with a degree of PcG pathway activation and would be informative in predicting the clinical behavior of prostate cancer in patients. Follow-up studies would be required to determine whether human prostate tumors manifesting markedly increased levels of dual positive high BMI1/Ezh2-expressing cells represent a therapy resistant clinically lethal type of prostate adenocarcinomas. Finally, this work sets the stage for development of small molecule inhibitors of the PcG protein chromatin silencing pathway as a novel therapeutic modality for treatment of metastatic prostate cancer. Figure 7 . Increased BMI1 and Ezh2 expression is associated with high likelihood of therapy failure and disease relapse in prostate cancer patients after radical prostatectomy (E). (D) Shows the Kaplan-Meyer survival analysis taking into account of the expression levels of both BMI1 ans Ezh2 genes. Kaplan-Meier survival analysis demonstrates that cancer patients with more significant elevation of the BMI1 and Ezh2 expression [having higher tumor (T) to adjacent normal tissue (N) ratio, T/N (A); or having tumors with higher levels of BMI1 (B) or Ezh2 (C) expression] are more likely to fail therapy and develop a disease recurrence after radical prostatectomy. (E) shows the Kaplan-Meier survival analysis of 79 prostate cancer patients stratified into five sub-groups using eight-covariate cancer therapy outcome (CTO) algorithm (Table 1) . CTO algorithm integrates individual prognostic powers of BMI1 and Ezh2 expression values and six clinicopathological covariates (preoperative PSA, Gleason score, surgical margins, extra-capsular invasion, seminal vesicle invasion, and age).
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